XXXX in Albania and the efficacy of its treatment with @entity2124 .

@entity1 @entity172 @entity851 @entity101 @entity1420 @entity1669 @entity2124 @entity854 @entity2689 @entity393
UNASSIGNED: The aim of this study was the evaluation of @entity2689 inside the Albanian population, its clinical, cytological and genetic characteristics, the accompanying pathologies, and the efficacy of the treatment with the @entity2124 . We performed a retrospective analysis of 59 @entity1 suffering from this syndrome (aging from 5 to 23 years old). The diagnosis of female @entity1 suffering from @entity2689 is delayed, with a mean age at the moment of diagnosis of 13.74 years (5-23 years). The main reason for seeking medical advice was the @entity851 or a delayed puberty. Available data for 52 @entity1 showed that the most frequent accompanying pathologies were the following: @entity1669 (59%), @entity854 (43%), renal pathologies (41%), @entity393 (4.3%) and @entity101 (3.3%). Follow-up for the growth rate was possible for 52 @entity1 out of the total of 59 @entity1 . Twenty-five of the female @entity1 suffering @entity2689 and forming part of our study sample were treated with @entity2124 for a period averaging 3 years and 4 months. A variety of reasons was identified as responsible for the missed treatment in 27 @entity1 . We saw an enhanced growth (in terms of body height) within the treated subgroup, when compared with the untreated subgroup (27 @entity1 ), especially during the first 3 years of the follow-up. No side effects of this treatment were reported. Both groups of @entity1 initiated as well a sexual hormone therapy ( @entity172 and @entity1420 ) for inducing puberty at the age of 12 years. Further work is needed for an early diagnosis of this syndrome, the prompt treatment with @entity2124 and the monitoring of accompanying disorders. This will ensure a better quality of life and an improvement of the longevity of @entity1 suffering from the @entity2689 .
